Galen Closes Majority Recapitalization of CDx Diagnostics

New York – July 27, 2017 – Cooley advised Galen Partners on completing a majority recapitalization of CDx Diagnostics, a specialized anatomic pathology laboratory. Debt financing was provided by White Oak Finance. Financial terms have not been disclosed.

“We are excited to back CDx’s proprietary computer-assisted cancer detection platform, and CDx is a perfect fit for Galen’s strategy of investing in companies that create value in healthcare,” said David Jahns, managing director of Galen Partners, in a news release.

CDx uses proprietary technology, including advanced neural-network analysis and deep artificial intelligence tools, to enhance the detection of precancerous and cancerous tissue initially for clinical use in the esophagus and oral cavity.

Galen partners, founded in 1999, is a leading healthcare-focused growth equity investment firm. With nearly $1 billion invested over five funds, Galen has helped build more than 70 companies since its inception.

The Cooley corporate team advising Galen included Ron Hopkinson, David Silverman, Brendan Koeth and Gloria Henderson. In addition, Patrick Flanagan, Sean Cornely and Frank Oliver advised on debt financing; Jeremy Naylor and Chris Mayer on tax; Phil Mitchell and Amy Westergen on healthcare; and Brian Hopkins on IP.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Ron Hopkinson Partner, New York
David Silverman Partner, New York
Brendan Koeth Associate, New York
Patrick Flanagan Partner, New York
Phil Mitchell Partner, New York
Brian Hopkins Special Counsel, New York